Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies.

In a post hoc analysis of 44 MODIFY I/II participants with inflammatory bowel disease, treatment with bezlotoxumab showed a trend toward a protective effect when compared with placebo, although the wide 95% CI does not allow for firm interpretations before the conducting of more powered studies on this topic [26.7% (4/15) vs. 53.8% (7/13), with difference − 27.2%, 95% CI − 57.9 to 9.6] [ 61 ].

also in 53,322 other papers